Health-related quality of life does not predict mortality in idiopathic pulmonary fibrosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 29, Issue 2, 2012, Pages 113-118

  Nishiyama, O ^a,b   Taniguchi, Hiroyuki ^a   Kondoh, Y ^a   Kimura, T ^a   Kataoka, K ^a   Nishimura, K ^c   Ogawa, T ^a   Watanabe, F ^a   Arizono, S ^a   Tohda, Y ^b  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c RAKUWAKAI OTOWA HOSPITAL   (Japan)

Author keywords

Health related quality of life; Idiopathic pulmonary fibrosis; Mortality

Indexed keywords

AGED; ARTICLE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; ST GEORGE RESPIRATORY QUESTIONNAIRE;

AGED; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; MALE; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SURVIVAL RATE; VITAL CAPACITY;

EID: 84872346919     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-64.
2. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137:129-37.
3. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203. (Pubitemid 28071283)
4. Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med 2005; 99: 408-14. (Pubitemid 40347823)
5. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-54. (Pubitemid 351831168)
6. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394-9. (Pubitemid 351503129)
7. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680-5. (Pubitemid 34971850)
8. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-9.
9. Raghu G, Brown KK, Bradford WZ, et al. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33. (Pubitemid 38056223)
10. Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42. (Pubitemid 41697286)
11. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
12. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-55.
13. King TE Jr, Albera C, Bradford WZ, et al. INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomized, placebo-controlled trial. Lancet 2009; 374: 222-8.
14. The Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-8.
15. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 1067-72.
16. Medical Section of the American Lung Association. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
17. Guideline of respiratory function tests: spirometry, flow volume curve, diffusion capacity of the lung. Nihon Kokyuki Gakkai Zasshi 2004; Suppl: 1-56.
18. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7.
19. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175-82. (Pubitemid 29535966)
20. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-81. (Pubitemid 33052246)
21. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005; 60: 588-94. (Pubitemid 40966214)